Sorrento Therapeutics Past Earnings Performance
Past criteria checks 0/6
Sorrento Therapeutics's earnings have been declining at an average annual rate of -27.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 5.2% per year.
Key information
-27.1%
Earnings growth rate
6.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 5.2% |
| Return on equity | n/a |
| Net Margin | -852.6% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Sorrento unit Scilex pre-emptively pays off remaining notes for $39.7M
Sep 29Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial
Sep 15Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103
Aug 31Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC
Aug 23Sorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH Trading
Aug 17Is Sorrento Therapeutics (NASDAQ:SRNE) A Risky Investment?
Jul 22
Sorrento Therapeutics: The Enigma
Jul 15Sorrento Therapeutics subsidiary Scilex to acquire Ancora Medical
Jul 07Sorrento Therapeutics: Sales Are Up But EY Identifies Internal Control Issues
Mar 15Sorrento Therapeutics: Wide Oncology Pipeline, And Watch Out For COVID Updates
Oct 09Revenue & Expenses Breakdown
How Sorrento Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 64 | -548 | 194 | 0 |
| 31 Mar 23 | 61 | -672 | 193 | 0 |
| 31 Dec 22 | 63 | -573 | 182 | 0 |
| 30 Sep 22 | 60 | -494 | 198 | 0 |
| 30 Jun 22 | 55 | -524 | 196 | 0 |
| 31 Mar 22 | 57 | -472 | 198 | 0 |
| 31 Dec 21 | 53 | -428 | 197 | 0 |
| 30 Sep 21 | 51 | -355 | 183 | 0 |
| 30 Jun 21 | 51 | -320 | 159 | 0 |
| 31 Mar 21 | 47 | -231 | 133 | 0 |
| 31 Dec 20 | 40 | -298 | 116 | 0 |
| 30 Sep 20 | 42 | -290 | 100 | 0 |
| 30 Jun 20 | 36 | -270 | 101 | 0 |
| 31 Mar 20 | 33 | -249 | 105 | 0 |
| 31 Dec 19 | 31 | -292 | 104 | 0 |
| 30 Sep 19 | 25 | -279 | 101 | 0 |
| 30 Jun 19 | 24 | -262 | 96 | 0 |
| 31 Mar 19 | 21 | -279 | 79 | 0 |
| 31 Dec 18 | 21 | -204 | 64 | 0 |
| 30 Sep 18 | 35 | -105 | 51 | 0 |
| 30 Jun 18 | 152 | -60 | 42 | 0 |
| 31 Mar 18 | 153 | 0 | 39 | 0 |
| 31 Dec 17 | 152 | 9 | 38 | 0 |
| 30 Sep 17 | 135 | -57 | 41 | 0 |
| 30 Jun 17 | 16 | -39 | 36 | 0 |
| 31 Mar 17 | 12 | -68 | 32 | 0 |
| 31 Dec 16 | 8 | -61 | 24 | 0 |
| 30 Sep 16 | 5 | -67 | 24 | 0 |
| 30 Jun 16 | 4 | -83 | 24 | 0 |
| 31 Mar 16 | 5 | -51 | 22 | 0 |
| 31 Dec 15 | 5 | -46 | 22 | 0 |
| 30 Sep 15 | 4 | -31 | 13 | 0 |
| 30 Jun 15 | 4 | -38 | 10 | 0 |
| 31 Mar 15 | 4 | -35 | 9 | 0 |
| 31 Dec 14 | 4 | -35 | 10 | 0 |
| 30 Sep 14 | 3 | -37 | 10 | 0 |
| 30 Jun 14 | 2 | -33 | 9 | 0 |
| 31 Mar 14 | 1 | -29 | 8 | 0 |
| 31 Dec 13 | 0 | -22 | 6 | 0 |
| 30 Sep 13 | 0 | -12 | 4 | 0 |
| 30 Jun 13 | 1 | -10 | 4 | 0 |
| 31 Mar 13 | 1 | -6 | 3 | 0 |
Quality Earnings: SRNE.Q is currently unprofitable.
Growing Profit Margin: SRNE.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SRNE.Q is unprofitable, and losses have increased over the past 5 years at a rate of 27.1% per year.
Accelerating Growth: Unable to compare SRNE.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SRNE.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: SRNE.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/04 04:25 |
| End of Day Share Price | 2024/01/03 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sorrento Therapeutics, Inc. is covered by 15 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| James Molloy | Alliance Global Partners |
| Difei Yang | Brean Capital |